NIPH Clinical Trials Search

Aprepitant for nausea, vomiting with the TC therapy of the gynecology cancer patient or the DC therapy, fosaprepitant, granisetron, protective efficacy of the dexamethasone combination therapy.

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	uterine cancer, ovarian cancer
Date of first enrollment	2011/05/01
Target sample size	140
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Aprepitant on days 1 to 3 (or fosapreitant on day1) Granisetron on day 1 Dexamethasone on days 1 to 4 Granisetron on day 1 Dexamethasone on days 1 to 4

Outcome(s)

Primary Outcome	The proportion of patients with No Emesis in overall phase (0-120 hours after administration of carboplatin on day 1)
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	70years-old
Gender	Female
Include criteria
Exclude criteria	1) Patient has a serious hepatic insufficiency or renal failure 2) Patient has nausea or vomiting within 24 hours prior to chemotherapy 3) Patient has been treated with antiemetic agents within 48 hours prior to chemotherapy 4) Patient has any illness (e.g. central nervous system tumors, gastrointestinal obstruction, active peptic ulcer, brain metastasis) caused nausea or vomiting except for chemotherapy-induced nausea and vomiting 5) Patient is scheduled to receive radiation therapy to the abdomen 6) Patient has the collateral symptom that the dosage of the dexamethasone is impossible for four days 7) Patient has received Pimozide 8) Patient is judged inappropriate by the investigator as subject for this study